Rick Satcher 0:03
Rick, good morning, everyone. I'm Rick Satcher, the director of commercialization for the Medical Technology Enterprise consortium more MTEC. MTEC is a 501 c3 or nonprofit that has partnered with the DOD, the Department of Defense, to invest in biomedical innovations that improves the health outcomes of our soldiers in the field, our veterans and civilians, we offer, I think, three key differentiators as a consortium, and the first is a direct dialog with our funding sponsors. This enables our companies and our network to have conversations about the requirements that the DOD has for novel products and any adjustments that would be necessary to submit proposals and responses to the solicitations that we provide, we also, through our contract mechanism, accelerate the process from solicitation to award, and that usually goes between four to six months. So we like to think of government operating at the speed of business. And then finally, one key differentiator as well is our commercialization support that we provide to our network. And I'll get more into that in a subsequent slide. So we have a large network, and the consortium 665, members, 70% of whom are small businesses. And you can see, since our inception in 16 our growth, and we continue to grow every year. Thus far, we're proud to announce that we've invested over $1 billion in medical product development. And these three pie charts show the awards by the type of business that we've awarded to, and over almost half is small business, and then our focus areas that include infectious disease, brain health and human performance work and also across disciplines. So we invest in therapeutics, healthcare, it medical devices and diagnostics and model development, our outcomes quite interesting. For every dollar that we invest, we receive between one and four fold multiple of additional follow on funding from both the public and the private sector. As I mentioned, earlier, our commercialization support to our members and our awardees includes the business strategy around market access, regulatory and other areas that are critical for preparing our companies to present in forums such as this, we also have developed relationships and partnerships with other accelerators. Matter health, for example, in Chicago, they have a FLEX program, and our members have access to this program that provides a lot of educational material and access to experts in different fields. And then we're developing collaborations and partnerships with strategics, with Angel investors and with venture capital. We have a partnership with Life Science angels here in California, and take part on some of their investment committees to learn more about how they work and to also provide feedback for our companies as they advance to the stages of seed and angel capital. So we invite you to join our network, right? We're looking for emerging biotech and medtech companies that fit what we consider to be military requirements that have a commercial market. So dual market concept, we invite our strategics. We've got a very large network of all the major players, but we're continuing to grow, and we request that you check us out and join us, as well as Angel and VC investors. And a quick shout out, we have our annual meeting, membership meeting coming up may 22 through 23rd in Baltimore, Maryland, and this is where you actually get to speak one on one with the funding sponsors. And we're also putting together similar to what we do here, partnering sessions, brief partnering sessions to enable our network to speak to one another. Okay, so reach out to us. Sean green is in the back. You wave, Sean. He's our he's our VP of strategies, our president to be great guy. Jill Sorensen is our Chief Development Officer, Dave hood, who many of you probably know resides out here on the West Coast, has been critical advisor to us and has been very beneficial. And then myself, the commercialization Our website is mtechy.org I'd invite anyone who is not in the network scroll down to the bottom of the home page and put your email address in, and you can see the solicitations that we release. And we release between six, eight up to 10 solicitation. Okay, so it's our honor to sponsor five of our networked companies here to present at LSI, limax Biosciences. Ben Friedman, I don't know if he's still in the audience. There he is, right there. He presented in an earlier session. He's developing hemo Max, which is, if you look at his his logo, it's based on snail slime. Snail slug slime, really, really cool technology, very fascinating. And then perceptive medical Joe Reinhart is actually presenting in an adjacent session right now. But first up here we have Sharif Solomon from matrogenics.
Rick Satcher 0:03
Rick, good morning, everyone. I'm Rick Satcher, the director of commercialization for the Medical Technology Enterprise consortium more MTEC. MTEC is a 501 c3 or nonprofit that has partnered with the DOD, the Department of Defense, to invest in biomedical innovations that improves the health outcomes of our soldiers in the field, our veterans and civilians, we offer, I think, three key differentiators as a consortium, and the first is a direct dialog with our funding sponsors. This enables our companies and our network to have conversations about the requirements that the DOD has for novel products and any adjustments that would be necessary to submit proposals and responses to the solicitations that we provide, we also, through our contract mechanism, accelerate the process from solicitation to award, and that usually goes between four to six months. So we like to think of government operating at the speed of business. And then finally, one key differentiator as well is our commercialization support that we provide to our network. And I'll get more into that in a subsequent slide. So we have a large network, and the consortium 665, members, 70% of whom are small businesses. And you can see, since our inception in 16 our growth, and we continue to grow every year. Thus far, we're proud to announce that we've invested over $1 billion in medical product development. And these three pie charts show the awards by the type of business that we've awarded to, and over almost half is small business, and then our focus areas that include infectious disease, brain health and human performance work and also across disciplines. So we invest in therapeutics, healthcare, it medical devices and diagnostics and model development, our outcomes quite interesting. For every dollar that we invest, we receive between one and four fold multiple of additional follow on funding from both the public and the private sector. As I mentioned, earlier, our commercialization support to our members and our awardees includes the business strategy around market access, regulatory and other areas that are critical for preparing our companies to present in forums such as this, we also have developed relationships and partnerships with other accelerators. Matter health, for example, in Chicago, they have a FLEX program, and our members have access to this program that provides a lot of educational material and access to experts in different fields. And then we're developing collaborations and partnerships with strategics, with Angel investors and with venture capital. We have a partnership with Life Science angels here in California, and take part on some of their investment committees to learn more about how they work and to also provide feedback for our companies as they advance to the stages of seed and angel capital. So we invite you to join our network, right? We're looking for emerging biotech and medtech companies that fit what we consider to be military requirements that have a commercial market. So dual market concept, we invite our strategics. We've got a very large network of all the major players, but we're continuing to grow, and we request that you check us out and join us, as well as Angel and VC investors. And a quick shout out, we have our annual meeting, membership meeting coming up may 22 through 23rd in Baltimore, Maryland, and this is where you actually get to speak one on one with the funding sponsors. And we're also putting together similar to what we do here, partnering sessions, brief partnering sessions to enable our network to speak to one another. Okay, so reach out to us. Sean green is in the back. You wave, Sean. He's our he's our VP of strategies, our president to be great guy. Jill Sorensen is our Chief Development Officer, Dave hood, who many of you probably know resides out here on the West Coast, has been critical advisor to us and has been very beneficial. And then myself, the commercialization Our website is mtechy.org I'd invite anyone who is not in the network scroll down to the bottom of the home page and put your email address in, and you can see the solicitations that we release. And we release between six, eight up to 10 solicitation. Okay, so it's our honor to sponsor five of our networked companies here to present at LSI, limax Biosciences. Ben Friedman, I don't know if he's still in the audience. There he is, right there. He presented in an earlier session. He's developing hemo Max, which is, if you look at his his logo, it's based on snail slime. Snail slug slime, really, really cool technology, very fascinating. And then perceptive medical Joe Reinhart is actually presenting in an adjacent session right now. But first up here we have Sharif Solomon from matrogenics.
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy